{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-015041","form_type":"8-K","ticker":"FLNA","cik":"0001069530","company_name":"FILANA THERAPEUTICS, INC.","filed_at":"2023-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.847117+00:00","generated_at":"2026-06-16T04:36:10.310616+00:00","sec_items":["1.02","1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Cassava Sciences terminates $100M SVB ATM, enters $200M ATM with JonesTrading","bullets":["Terminated SVB Securities ATM agreement effective May 1, 2023; no shares ever sold under that facility.","Entered new Capital on Demand Sales Agreement with JonesTrading for up to $200M aggregate offering price.","New ATM replaces prior program; shares sold via 'at the market' offerings under new shelf registration statement S-3.","JonesTrading receives commission up to 3% of gross proceeds; company reimburses certain expenses.","No obligation to sell shares; company can set minimum price and suspend or terminate offering."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-015041","json":"https://secwatch.observer/filing/0001493152-23-015041.json","markdown":"https://secwatch.observer/filing/0001493152-23-015041.md","text":"https://secwatch.observer/filing/0001493152-23-015041.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1069530/000149315223015041/0001493152-23-015041-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1069530/000149315223015041/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T04:36:10.310616+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b0bf89ad1f88cb447b7fc83ebe107211d91f6df8","claim":"FILANA THERAPEUTICS, INC. terminated SVB Sales Agreement with SVB Securities LLC (f/k/a SVB Leerink LLC) valued at up to $100,000,000 (effective 2023-05-01).","evidence_excerpt":"On April 26, 2023, the Company provided SVB with notice of termination of the SVB Sales Agreement, effective May 1, 2023.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1069530/000149315223015041/0001493152-23-015041-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"atm program"},{"label":"Counterparty","value":"SVB Securities LLC (f/k/a SVB Leerink LLC)"},{"label":"Value","value":"up to $100,000,000"},{"label":"Effective","value":"2023-05-01"}],"fact_type":"material_agreement"},{"claim_id":"faade93f4bfb080dc9110650d278412b96a0240e","claim":"FILANA THERAPEUTICS, INC. entered into Capital on DemandTM Sales Agreement with JonesTrading Institutional Services LLC valued at up to $200,000,000 (effective 2023-05-01).","evidence_excerpt":"On May 1, 2023, the Company entered into a Capital on DemandTM Sales Agreement (the “Sales Agreement”) with JonesTrading Institutional Services LLC, as agent (“Agent”), pursuant to which the Company may offer and sell, from time to time through or to the Agent, shares of the Company’s common stock, par value $0.001 per share (the “Shares”), having an aggregate offering price of up to $200,000,000 (the “Offering”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1069530/000149315223015041/0001493152-23-015041-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"atm program"},{"label":"Counterparty","value":"JonesTrading Institutional Services LLC"},{"label":"Value","value":"up to $200,000,000"},{"label":"Effective","value":"2023-05-01"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}